Matritech and Bayer in cervical test tie-up
This article was originally published in Clinica
Bayer will gain the rights to develop new cervical cancer detection systems based on Matritech's patented Nuclear Matrix Protein (NMP) technology under a product development and marketing option agreement just signed with the US based company. In return, Matritech would receive an initial payment plus further milestone and option payments. If Bayer's US Diagnostics Division exercises its marketing option, it will have the exclusive worldwide right to sell automated NMP-based cervical cancer systems utilising raw materials supplied by its new partner.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.